See how Zendal overcame multiple challenges of cybersecurity, incompatible equipment, lockdown, logistics, and remote teams.
During the year 2020, dozens of companies worldwide worked to develop vaccines for the pandemic-causing virus COVID-19. Biofabri, a subsidiary of Spanish international biopharmaceutical group Zendal, became responsible for industrial production of the antigen vaccine for most of Europe.
Their task was daunting. Somehow they would have to construct and automate a new fill-and-finish facility during a worldwide pandemic, in a country with one of the strictest lockdowns. Logistics were soon in chaos, with even basic supplies unavailable. Zendal had a variety of older equipment in place with incompatible controllers and individual HMIs. They also had no control over the make or model of PLCs that package suppliers would provide with new equipment.
And towering over all other problems were issues of cybersecurity.